{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:34:39Z","timestamp":1771868079850,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2242,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1093\/annonc\/mdt298","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T05:56:05Z","timestamp":1380261365000},"page":"vi155-vi159","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S6","title":["Waldenstr\u00f6m's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"24","author":[{"given":"C.","family":"Buske","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt298_bb0010","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstr\u00f6m's macroglobulinemia: incidence patterns in the United States, 1988\u20131994","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt298_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.leukres.2007.02.002","article-title":"The incidence and survival of Waldenstr\u00f6m's Macroglobulinaemia in South East England","volume":"32","author":"Phekoo","year":"2008","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdt298_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt298_bb0030","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt298_bb0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3816\/CLM.2009.n.027","article-title":"Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstr\u00f6m's macroglobulinemia","volume":"9","author":"Menke","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdt298_bb0040","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt298_bb0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","article-title":"Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0060","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdt298_bb0070","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt298_bb0075","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdt298_bb0080","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0085","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0090","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt298_bb0095","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt298_bb0105","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4065\/mcp.2010.0304","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines","volume":"85","author":"Ansell","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1093\/annonc\/mdt298_bb0110","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0115","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstr\u00f6m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt298_bb0120","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/leu.2013.36","article-title":"How to manage Waldenstrom's macroglobulinemia","volume":"27","author":"Buske","year":"2013","journal-title":"Leukemia"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/suppl_6\/vi155\/6676186\/mdt298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T14:06:41Z","timestamp":1635775601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419315583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":23,"alternative-id":["S0923753419315583"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt298","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}